Multicenter study reports significant cost impact of transthyretin amyloid cardiomyopathy in heart failure patients, suggesting implications for healthcare budgeting.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Garcia-Pavia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: